[WOUNDS OF THE ABDOMINAL AORTA ( 2 CASES OPERATED ON AND RECOVERED)].

J. Cormier

Abstract:

What problem does this paper attempt to address?

Introduction: Strategies for developing genetically modified mice.

M. Hofker

DOI: https://doi.org/10.1007/978-1-60761-974-1_1

Abstract:
Isolated Neurosarcoidosis Mimicking Multifocal Meningiomas: A Diagnosis Pitfall A Case Report

Kun Wang,Baying He,Wei Wang,Huanjiang Niu,Yirong Wang,Xiujun Cai,Shuxu Yang

DOI: https://doi.org/10.1097/md.0000000000004994

IF: 1.6

2016-01-01

Medicine

Abstract:Introduction: Neurosarcoidosis accounts for approximately 5% of the sarcoidosis, which develops exclusively in the nervous system and is always difficult to diagnose. We describe a rare case of isolated neurosarcoidosis mimicking as multifocal meningiomas. A 27-year-old male was admitted to our hospital with a history of unconsciousness and convulsion 1 month ago, which was suspected as a seizure. The results showed no abnormalities in complete blood count; serum electrolytes; erythrocyte sedimentation rate and ultrasonography of the liver, pancreas, spleen, kidney and parotid gland, and so on. Chest radiograph and electroencephalogram were also normal. Serum-angiotensin-converting enzyme slightly increased. Normal opening pressure was shown in cerebrospinal fluid sampling, which includes 8/mL white blood cells, 0.93 g/L protein, and 3.03mmol/L glucose. Enhanced magnetic resonance imaging revealed multifocal enhancement lesions, including left sphenoid wing region, left temporal and bilateral occipitoparietal region, which were suspected as multiple "meningioma". A left frontotemporal craniotomy was further performed. Both necrotizing and non-necrotizing granulomas were revealed in the pathological specimen, most of which were associated with multinucleated giant cells and macrophages. We could also see the fibrosis and inflammatory reaction in the sample composed of lymphocytes, histiocytes, and plasma cells. Histopathological examination showed that the cells were positive for human CD68 (KP1), CD68 (PGM1), and CD163; however, they were negative for the AF, epithelial membrane antigen, and glial fibrillary acidic protein. Tuberculosis-deoxyribonucleic acid test and special stains for acid-fast bacilli and fungi were negative. The diagnosis was finally made as isolated neurosarcoidosis. Then the patient was treated with additional corticosteroid therapy. Serial imaging examination 4 months later revealed that the lesions extremely decreased.Conclusion: The diagnosis of isolated central nervous system sarcoidosis was still difficult because of limitations of available diagnostic tests. So neurosarcoidosis in the clinical work should never be neglected.
[Education of the autistic child].

P. Lenoir,C. Barthélémy

Soins Psychiatrie

Abstract:
Central Nervous System Sarcoidosis: A National-Based registry study

Yazan Al-Zamer,Sami Al-Horani,Marah Akhdar,Ghaydah Majali,Hamza Alzghoul,Moustafa Younis,Pouya Ameli,Bashar Alzghoul

DOI: https://doi.org/10.36141/svdld.v41i3.15103

2024-09-24

Abstract:Background and aim: Sarcoidosis of the central nervous system (CNS) often presents deleterious effects on affected patients. Data and available literature discussing the diagnosis and treatment of this condition are scarce and inconsistent. In this study, we aim to shed light on demographics, management, diagnostics, and clinical complications of CNS sarcoidosis patients within the United States (US) based on a nation-wide registry questionnaire. Methods: Our retrospective study was conducted based on a national registry investigating 3,835 respondents to the Foundation for Sarcoidosis Research Sarcoidosis Advanced Registry for Cures Questionnaire (FSR-SARC). This national registry data was collected during the period of June 2014 to August 2019. We performed propensity score matching, summary, univariate, and multivariate analyses to establish a comparison between the presence and absence of central nervous system sarcoidosis. Results: We identified a total of 420/3634 (11.55%) patients having CNS sarcoidosis; 296 (70.5%) were females, 307 (73.1%) were Caucasian and 81 (19.3%) were African American. The mean (±SD) age at diagnosis of CNS sarcoidosis was 43.3 (±12) years old. Multiorgan involvement (≥3 organs) was present in 318/420 (75.7%) patients. Brain magnetic resonance imaging was the most common ancillary diagnostic modality used and reported to be abnormal 251/328 (76.5%). Corticosteroids were the most used treatment by CNS sarcoidosis patients 206/420 (49.0%) followed by cytotoxic agents 180/420 (42.9%). Conclusions: CNS sarcoidosis prevalence in our cohort was similar to what has been described previously. The most prevalent imaging modality used was cranial MRI. Corticosteroids were the most used medications. Lastly, CNS sarcoidosis showed a propensity to cause several clinical complications such as chronic pain syndrome and disability.
A Single Center Cross-Sectional Study of Clinical Outcomes

Rami Al-Hader,Justin Nofar,Ahmed Mohamedelkhair,Muhammad Affan,Lonni R. Schultz,Mirela Cerghet

DOI: https://doi.org/10.3390/jcm13175069

IF: 3.9

2024-08-29

Journal of Clinical Medicine

Abstract:Background/Objective: To describe the clinical features and radiological outcomes of patients with spinal cord neurosarcoidosis, treatments, and long-term follow-up for this rare disorder. Methods: A cross-sectional, retrospective medical chart review was performed for all patients with spinal cord neurosarcoidosis treated at a single center between 01/1995 and 12/2020. Radiological imaging, laboratory test results, the type of immunosuppressive therapy, and function test scores were reviewed. Results: We assessed 39 patients with spinal cord neurosarcoidosis (23 men, 16 women, mean age at presentation 46.4 years, SD 10.2 years). The mean (SD) duration of spinal cord neurosarcoidosis at data abstraction was 9.8 (6.3) years. There were 24 patients (62%) with extensive intramedullary lesions, 8 (21%) with multiple patchy intramedullary lesions, 12 (31%) with leptomeningeal involvement, and 7 (18%) with nerve root enhancement. The cervical spine was the most commonly affected region in 33 patients (85%). The most common presenting symptoms were paresthesia/neuropathic pain in 20 (51%) and weakness of extremities in 15 (38%) patients. Most patients (n = 37; 95%) had been treated with corticosteroids at symptom onset, and methotrexate was the most used immunosuppressive therapy (n = 19; 49%). Of 34 patients with follow-up magnetic resonance imaging (MRI) available, the median time to improvement per MRI was 10.8 months (95% CI, 6.1–17.0 months). Of 31 patients with MRI enhancement at presentation, 18 (58%) had complete enhancement resolution at follow-up, with a median time to resolution of 51.8 months (95% CI, 24.9–83.4 months). Patients had significantly lower pyramidal (p = 0.004) and sensory functional (p = 0.031) systems scores from presentation to the last clinic visit. Conclusions: Because spinal cord neurosarcoidosis is challenging to diagnose and no set treatment guidelines exist, clarifying patients' clinical parameters and responses to various treatments is needed to improve timely and efficient care. The incidence of spinal cord involvement in sarcoidosis in our cohort was higher than intracranial involvement and most patients had a long extensive intramedullary lesion. We also observed that most patients with spinal cord neurosarcoidosis improved clinically and radiologically after treatment; however, the resolution of MRI enhancement after immunosuppressive therapy may take years. Prospective studies of neurosarcoidosis will be crucial to address questions about effective treatment and long-term prognosis.

medicine, general & internal
Diagnostic challenges of neurosarcoidosis in non-endemic areas

Keshari Shrestha,B. K. Kleinschmidt-DeMasters,D. Ryan Ormond

DOI: https://doi.org/10.3389/fneur.2023.1220635

IF: 3.4

2024-01-12

Frontiers in Neurology

Abstract:Background: Neurosarcoidosis (NS) is a challenging diagnosis, particularly when cases occur in low-prevalence, non-endemic geographic regions. In the United States, the highest incidence is in the Midwest and Northeast, compared to our Southwest location. While it is well known that NS may clinically and neuroradiographically mimic meningeal carcinomatosis, autoimmune or infectious pachymeningitis, neurosyphilis, or tuberculosis, diagnosis may be particularly challenging if systemic signs of sarcoidosis are lacking or unconfirmed or if dural-based masses are present. We reviewed our Colorado experience with NS cases, focusing our study on cases where NS represented the first histological confirmation of disease. Methods: A search of departmental databases was conducted with the search term "neurosarcoidosis" to identify cases 1-2008 to 12-2019, inclusive of the given case numbers. Patients were only included if their clinical and neuroimaging features were unusual and only when a biopsy of the central nervous system (CNS) represented the first confirmed diagnosis of sarcoidosis. Results: A total of 17 cases were identified, of which the biopsy of the CNS was used for the initial confirmation of the disease in 9 of them. The most unusual findings were two patients with dural-based masses, one of which had pure NS as the cause of meningioma-like lesions and the second of which had coexistent meningioma and intimately admixed non-necrotizing granulomas of NS. Conclusion: NS with unusual features, especially in non-endemic areas, continues to yield diagnostic challenges for neurologists, neuroradiologists, and pathologists.

neurosciences,clinical neurology
Sarcoidosis of the central nervous system: Safety and efficacy of treatment, and experience of biological therapies

Desmond P Kidd,Desmond P. Kidd

DOI: https://doi.org/10.1016/j.clineuro.2020.105811

IF: 1.885

2020-07-01

Clinical Neurology and Neurosurgery

Abstract:Neurosarcoidosis is very rare and the natural history under-researched.The optimum treatment and treatment outcome has been studied and the results presented.A treatment paradigm may be established.Further research into optimization of treatment in the disease may be established.Neurological complications of sarcoidosis are uncommon and the natural history and optimal treatments under-researched. With the advent of biological therapies, it is important to define the clinical characteristics and immunopathology of the disease.Patients and methods: Patients referred to and treated within the Centre for Neurosarcoidosis over a 15 year period who had biopsy proven "highly probable" disease of the central nervous system were studied prospectively.Corticosteroids were used effectively in all patients, immunosuppression in 79% and TNFα antagonists in 23%. Treatment with steroids alone inevitably led to relapse, and low dose immunosuppression was ineffective in those with severe forms of the disease. Use of biological therapies substantially improved outcome.Patients with cranial neuropathy had an excellent outcome. Those with pachymeningitis had marked radiological abnormalities but less disablement. Those with leptomeningitis had an invasive, destructive disease which responded well to treatment but with residual neurological impairments. Treatment was required for many years, but the risk of relapse following treatment withdrawal was low. Infective complications arose in six. There were two deaths, neither directly related to the neurological disease, nor its treatment.This prospective study of the natural history and treatment response in neurosarcoidosis provides evidence that the use of high dose immunosuppression and early and prolonged use of biological therapies is associated with greatly improved outcomes and lower mortality. The data may be used to plan further studies and treatment trials, and provide class IV evidence for the effectiveness of biological agents in the treatment of Neurosarcoidosis.

surgery,clinical neurology
[Sarcoid Peripheral Neuropathy and Myopathy: A Diagnostic and Therapeutic Challenge]

Miwako Fujisawa

DOI: https://doi.org/10.11477/mf.1416202649

Abstract:Sarcoidosis is an idiopathic granulomatous multi-organ disease, primarily affecting the respiratory system, eyes, and skin, with less involvement in peripheral neurons and muscles. Sarcoid peripheral neuropathy encompasses cranial and spinal nerve impairment. Muscle involvement is often asymptomatic and revealed through imaging. Symptomatic muscle involvement is categorized into three clinical types: nodular myopathy, acute myopathy, and chronic myopathy. The identification of noncaseating granulomas in peripheral nerves or muscles, coupled with the exclusion of other diseases, is essential for establishing a definitive diagnosis of sarcoid peripheral neuropathy and myopathy. Sarcoid neuropathy and myopathy are typically managed with high-dose corticosteroids, immunosuppressants, or a combination of both. In recent times, the use of TNF-alpha inhibitors has notably increased. However, these conditions often exhibit resistance to treatment and may necessitate prolonged therapeutic interventions. Therefore, comprehensive examinations should be conducted before considering immunotherapy. Due to the rarity of these conditions, research on manifestation-specific treatments is lacking, and standard treatments for sarcoid neuropathy and myopathy have not been established. Additional treatment options for sarcoid neuropathy and myopathy are expected to become available in the future.
Eder‐Puestow Oesophageal Dilatation

W. McAdam,A. G. Morgan,A. Darnborough

DOI: https://doi.org/10.1002/BJS.1800671222

1980-12-01

Abstract:technique to our own data and whilst there can be few clinical situations in which this added information is likely to be of value, we note it with interest. We have looked at the transit times of "Tcm-HIDA in the liver and applied this to the assessment of the jaundiced patient. In our own experience the accumulation of IDA within the liver deteriorated as the serum bilirubin became elevated. The bilirubin was a better parameter of the ability of the liver to accumulate HlDA than either alanine aminotransferase or the alkaline hosphatase levels. We found that the images were difficuE to interpret for bilirubins of 100150 u/l and impossible for levels above this. We are currently assessing the relative efficacies of "Tc"'HIDA with "'Tcm p-Butyl IDA in hepatobiliary scanning. r. v. TAYLOR University Department of Clinical Surgery The Royal Infirmary Edinburgh EH3 9YW intrakepatic duct. We have not applied this subtraction
Diagnostic and Therapeutic Insights into Pediatric Neurosarcoidosis: Observations from French Pediatric Rheumatology Centers

Racha Tohme,Anca Tanase,Cécile Dumaine,Perrine Dusser,Homa Adle-Biassette,Veronique Despert,Albert Faye,Inès Mannes,Isabelle Melki,Isabelle Kone-Paut,Ulrich Meinzer

DOI: https://doi.org/10.1016/j.pediatrneurol.2024.10.007

IF: 4.21

2024-10-20

Pediatric Neurology

Abstract:Background The diagnosis and management of neurosarcoidosis in pediatric patients present significant challenges, with few documented cases available to guide health care providers. Existing reports focus mainly on the initial manifestations. Our aim was to describe the clinical presentation, management and medium-term evolution of neurosarcoidosis in children. Methods In this retrospective, multi-centric, observational study we collected data from pediatric patients followed in French pediatric rheumatology centers with a diagnosis of neurosarcoidosis between January 2001 and June 2023. Results We identified 11 patients diagnosed with neurosarcoidosis, comprising 8 girls and 3 boys. The mean age at diagnosis of sarcoidosis was 10 [5-15] years and the mean age of diagnosis of NS was 11.5 [5-17] years. Predominant neurological symptoms included headache (9/11 patients), papilledema (6/11 patients), facial palsy in 2 patients, seizures in one patient and motor deficit in two patients. 9/11 patients had eye involvement, which consisted of granulomatous, bilateral uveitis. All patients exhibited meningitis, with CSF white blood cell counts ranging from 6 to 70 cells/mm 3 . Six individuals presented neurological abnormalities on imaging, detailed in this study. The main treatment regimen involved corticosteroids, methotrexate and TNF-alpha inhibitors. Biologics targeting TNF-alpha were necessary to achieve remission in 8/11 patients. In two patients who did not receive this treatment initially, it was required later in the course of evolution. Conclusions This study contributes to the comprehension of the clinical course of NS in pediatric populations and reinforces the recommendation for the early consideration of biologics targeting TNF-alpha in children with NS.

pediatrics,clinical neurology
Neurosarcoidosis manifesting as cavernous sinus syndrome in systemic sarcoidosis

Manxin Gao,Gi Tae Kwon,Mohammad Ruhul Amin

DOI: https://doi.org/10.1136/bcr-2024-259714

2024-07-16

Abstract:Neurosarcoidosis can manifest in various neurological presentations. The occurrence of cavernous sinus involvement in neurosarcoidosis is rare, which can complicate the diagnostic process. We present a case of neurosarcoidosis demonstrating progressively deteriorating right cavernous sinus syndrome in a woman in her 50s, affecting the oculomotor, abducens and the ophthalmic division of the trigeminal nerves. MRI demonstrated meningeal thickening along the lateral wall of the right cavernous sinus, and a pan-CT scan of the chest, abdomen and pelvis revealed disseminated sarcoidosis involving the lungs and the liver. Histopathological analysis of the liver lesion ultimately confirmed the diagnosis of sarcoidosis. This case underscores the significance of considering neurosarcoidosis as a potential cause of cavernous sinus syndrome. In such cases, early initiation of corticosteroid treatment, with or without steroid-sparing agents, is crucial to prevent disease progression and relapse.
[Future drug targets for Parkinson's disease].

E. Hirsch

DOI: https://doi.org/10.1016/S0001-4079(19)31718-2

2012-10-01

Abstract:
Cerebrospinal Fluid Cytokine and Chemokine Profiles in Central Nervous System Sarcoidosis: Diagnostic and Immunopathologic Insights

Georgios Mangioris,Sean J. Pittock,Binxia Yang,James P. Fryer,William S. Harmsen,Divyanshu Dubey,Eoin P. Flanagan,Sebastian A. Lopez‐Chiriboga,Andrew McKeon,John R. Mills,Ivana Vodopivec,W. Oliver Tobin,Michel Toledano,Allen J. Aksamit,Anastasia Zekeridou

DOI: https://doi.org/10.1002/ana.27024

IF: 11.2

2024-07-20

Annals of Neurology

Abstract:Objective To evaluate the cerebrospinal fluid (CSF) cytokine/chemokine profile of central nervous system (CNS) neurosarcoidosis (NS), and its utility in differential diagnosis, treatment, and prognostication. Methods In this case–control study, we validated 17 cytokines/chemokines (interleukin [IL]‐1‐beta, IL‐2, IL‐4, IL‐5, IL‐6, IL‐10, IL‐12p70, IL‐13, IL‐17A, BAFF, IL‐8/CXCL8, CXCL9, CXCL10, CXCL13, GM‐CSF, interferon‐gamma, and tumor necrosis factor [TNF]‐alpha) in a multiplexed automated immunoassay system (ELLA; Bio‐Techne, Minneapolis, MN, USA), and assessed them in CSF and serum of symptomatic patients with probable or definite CNS NS (01/2011–02/2023) with gadolinium enhancement and/or CSF pleocytosis. Patients with multiple sclerosis, primary CNS lymphoma, aquaporin‐4 immunoglobulin G positivity, non‐inflammatory disorders, and healthy individuals were used as controls. Results A total of 32 NS patients (59% women; median age, 59 years [19–81]) were included; concurrent sera were available in 12. CSF controls consisted of 26 multiple sclerosis, 8 primary CNS lymphoma, 84 aquaporin‐4 immunoglobulin G positive, and 34 patients with non‐inflammatory disorders. Gadolinium enhancement was present in 31 of 32 NS patients, and CSF pleocytosis in 27 of 32 (84%). CSF IL‐2, IL‐6, IL‐10, IL‐13, BAFF, IL‐8/CXCL8, CXCL9, CXCL10, CXCL13, GM‐CSF, interferon‐gamma, and TNF‐alpha levels were significantly higher in NS patients compared with non‐inflammatory controls (p ≤ 0.02); elevations were more common in CSF than serum. Concurrent elevation of IL‐6, CXCL9, CXCL10, GM‐CSF, interferon‐gamma, and TNF‐alpha was present in 18 of 32 NS patients, but only in 1 control. Elevated IL‐6, IL‐10, IL‐13, CXCL9, CXL10, GM‐CSF, and TNF‐alpha associated with measures of disease activity. Interpretation NS CSF cytokine/chemokine profiles suggest T cell (mainly T helper cell type 1), macrophage, and B‐cell involvement. These signatures aid in NS diagnosis, indicate disease activity, and suggest therapeutic avenues. ANN NEUROL 2024

neurosciences,clinical neurology
Benign Intracranial Hypertension: A Rare Manifestation of Neurosarcoidosis

Prashant Dubey,Satish Nirhale,Shalesh Rohatgi,Pranit Khandait

DOI: https://doi.org/10.7759/cureus.43363

2023-08-12

Cureus

Abstract:Sarcoidosis is an immune-mediated disease that can involve multiple systems. Sarcoidosis of the nervous system or neurosarcoidosis may present as cranial mononeuropathy, hypothalamic involvement, aseptic meningitis, granulomatous inflammation in the brain parenchyma or spinal cord, peripheral neuropathy, and, in rare cases, as myopathy and benign intracranial hypertension. The most common cranial nerve involvement is the facial nerve, which can present as unilateral or bilateral facial nerve palsy, often with recurrent episodes. Involvement of other cranial nerves such as the second and eighth cranial nerves has also been reported. Granulomatous inflammation in the spinal cord presents as myelopathy or radiculopathy. Peripheral neuropathy can manifest as mononeuropathy, mononeuritis multiplex, or generalized sensory-motor neuropathy. Carpal tunnel syndrome is more common in patients with sarcoidosis compared to the general population. Here, we describe the case of a 40-year-old female who presented with heaviness of the head and blurred vision, with a prior history of left-sided Bell's palsy. Bilateral papilledema was observed during the fundus examination. MRI of the brain revealed signs suggestive of benign intracranial hypertension. The cerebrospinal fluid (CSF) opening pressure was measured at 40 cmH2O. Biopsy of bilateral hilar lymphadenopathy indicated granulomatous inflammation consistent with sarcoidosis. The patient was started on steroids and acetazolamide, and she had a dramatic improvement in symptoms.
Neurosarcoidosis Masquerading as Spinal Stenosis

Ameen Batheesh,Nina Borissovsky,Devy Zisman,Tal Gazitt

DOI: https://doi.org/10.3390/diagnostics14202296

IF: 3.6

2024-10-17

Diagnostics

Abstract:A 65-year-old woman was admitted to the neurology department with a suspected demyelinating disease due to complaints of progressive pain and weakness in both upper and lower limbs, as well as urinary incontinence. MRI of the spine revealed complex disc osteophyte with compression of the spinal cord in the cervical and lumbar spine at several vertebral levels, and localized enhancement in the cervical spine at the site of maximal spinal canal stenosis. During her hospitalization, the patient underwent extensive evaluation to rule out any systematic inflammatory diseases, infections, and malignancy. Chest CT revealed bilateral mediastinal lymphadenopathy. Transbronchial mediastinal lymph node biopsy showed numerous non-necrotizing granulomas without evidence of malignancy. After a thorough and careful exclusion of a demyelinating, infectious, and paraneoplastic myelopathies, and based on clinical, radiographic, and pathological findings, the patient was diagnosed with both neurosarcoidosis and spondylotic myelopathy. She was then treated for neurosarcoidosis, including glucocorticosteroids, azathioprine, and a biosimilar of the anti-TNF alpha agent infliximab, resulting in both clinical and radiographic improvement. Intramedullary spinal neurosarcoidosis is very rare and may present with clinical features of spondylotic myelopathy, with typical imaging findings occurring only in areas of spinal canal stenosis.

medicine, general & internal
Etanercept for Sleep in Patients with Alcohol Use Disorder—Mechanisms Need to be Elucidated

R. Krishnadas

DOI: https://doi.org/10.1016/j.biopsych.2009.06.019

IF: 12.81

2010-01-01

Biological Psychiatry

Abstract:
Teaching Power Electronics using the switching function approach

C. Marouchos,M. Darwish

DOI: https://doi.org/10.1109/UPEC.2012.6398595

2012-12-31

Abstract:The teaching of Power Electronics at university Level can be simplified and can be more effective by employing the Switching Function Technique. A unified approach to the operation and analysis of any power converter circuit is possible. The authors tried this approach for a number of years at the Cyprus University of Technology and at Brunel University. This teaching approach is based on the identification of the appropriate switching function which can be applied to a power converter. The switching function is a series of pulses of unity magnitude and it is expressed as a series of sinusoids and its parameters are the ON period of the pulses as well as their phase angles. Analytical expressions of current and voltage waveforms are derived at any point of the circuit -preferably the input and output- as a series of sinusoids. This makes the identification of the order of the harmonics straightforward and the calculation of harmonic magnitude & phase, THD, PF etc. possible.
Recent advances in sarcoidosis

Adam S Morgenthau,Michael C Iannuzzi

DOI: https://doi.org/10.1378/chest.10-0188

IF: 9.6

Chest

Abstract:Sarcoidosis, a systemic granulomatous disease of undetermined etiology, is characterized by a variable clinical presentation and course. During the past decade, advances have been made in the study of sarcoidosis. The multicenter ACCESS (A Case Control Etiologic Study of Sarcoidosis) trial recruited > 700 subjects with newly diagnosed sarcoidosis and matched control subjects. Investigators were unable to identify a single cause of sarcoidosis, but ACCESS paved the way for subsequent etiologic studies. The Mycobacterium tuberculosis catalase-peroxidase protein has been identified as a potential sarcoidosis antigen. Genetic aspects of the disease have been elucidated further. Genome-wide scans have identified candidate genes. Gene expression analyses have defined cytokine dysregulation in sarcoidosis more clearly. Although the criteria for diagnosis have not changed, sarcoidosis remains a diagnosis of exclusion best supported by a tissue biopsy specimen that demonstrates noncaseating granulomas in a patient with compatible clinical and radiologic features of the disease. Endobronchial ultrasound-guided transbronchial needle aspiration of mediastinal lymph nodes has facilitated diagnosis, often eliminating the need for more invasive procedures, such as mediastinoscopy. PET scanning has proven valuable in locating occult sites of active disease. Currently, no reliable prognostic biomarkers have been identified. The tumor necrosis factor inhibitors, a relatively new class of agents, have been used in patients with refractory disease. It is unclear whether phosphodiesterase-5 inhibitors, prostaglandin analogs, or endothelin antagonists should be used for the treatment of sarcoidosis-associated pulmonary hypertension.
Diagnostic and management strategies in cardiac sarcoidosis

Jasmine K Malhi,Chukwuka Ibecheozor,Jonathan Chrispin,Nisha A Gilotra,Jasmine K. Malhi,Nisha A. Gilotra

DOI: https://doi.org/10.1016/j.ijcard.2024.131853

IF: 4.039

2024-02-19

International Journal of Cardiology

Abstract:Cardiac sarcoidosis (CS) is increasingly recognized in the context of with otherwise unexplained electrical or structural heart disease due to improved diagnostic tools and awareness. Therefore, clinicians require improved understanding of this rare but fatal disease to care for these patients. The cardinal features of CS, include arrhythmias, atrio-ventricular conduction delay and cardiomyopathy. In addition to treatments tailored to these cardiac manifestations, immunosuppression plays a key role in active CS management. However, clinical trial and consensus guidelines are limited to guide the use of immunosuppression in these patients. This review aims to provide a practical overview to the current diagnostic challenges, treatment approach, and future opportunities in the field of CS.

cardiac & cardiovascular systems
Systemic and Neurosarcoidosis With Rare Involvement of the Extremities' Peripheral Nerves

Fathima Fijula Palot Manzil,Joshua Eichhorn,Harleen Kaur

DOI: https://doi.org/10.1097/rlu.0000000000005176

IF: 10.6

2024-05-05

Clinical Nuclear Medicine

Abstract:We present a case of sarcoidosis with a rare presentation of involvement of peripheral nerves of the lower limbs and subcutaneous nodules detected on 18F-FDG PET/CT. The patient also had involvement of the spinal nerves and dura, histologically proven to be sarcoidosis. There were other manifestations of systemic sarcoidosis like metabolically active cervical and mediastinal lymphadenopathy. This case highlights the role of 18F-FDG PET/CT in evaluating the uncommon sites of sarcoid involvement. Although many cases of sarcoid involvement of central nervous system have been reported, peripheral nerves involvement in the extremities was not found on a literature search.

radiology, nuclear medicine & medical imaging

[WOUNDS OF THE ABDOMINAL AORTA ( 2 CASES OPERATED ON AND RECOVERED)].

Introduction: Strategies for developing genetically modified mice.

Isolated Neurosarcoidosis Mimicking Multifocal Meningiomas: A Diagnosis Pitfall A Case Report

[Education of the autistic child].

Central Nervous System Sarcoidosis: A National-Based registry study

A Single Center Cross-Sectional Study of Clinical Outcomes

Diagnostic challenges of neurosarcoidosis in non-endemic areas

Sarcoidosis of the central nervous system: Safety and efficacy of treatment, and experience of biological therapies

[Sarcoid Peripheral Neuropathy and Myopathy: A Diagnostic and Therapeutic Challenge]

Eder‐Puestow Oesophageal Dilatation

Diagnostic and Therapeutic Insights into Pediatric Neurosarcoidosis: Observations from French Pediatric Rheumatology Centers

Neurosarcoidosis manifesting as cavernous sinus syndrome in systemic sarcoidosis

[Future drug targets for Parkinson's disease].

Cerebrospinal Fluid Cytokine and Chemokine Profiles in Central Nervous System Sarcoidosis: Diagnostic and Immunopathologic Insights

Benign Intracranial Hypertension: A Rare Manifestation of Neurosarcoidosis

Neurosarcoidosis Masquerading as Spinal Stenosis

Etanercept for Sleep in Patients with Alcohol Use Disorder—Mechanisms Need to be Elucidated

Teaching Power Electronics using the switching function approach

Recent advances in sarcoidosis

Diagnostic and management strategies in cardiac sarcoidosis

Systemic and Neurosarcoidosis With Rare Involvement of the Extremities' Peripheral Nerves